Background: Addressing the Critical Blind Spots of Conventional Single-Point Omics and the Bottleneck of Clonal Evolution Data in R&D for Intractable Diseases

Tumor heterogeneity, aging-associated decline in biological functions, and post-myocardial infarction tissue fibrosis are pathological phenomena that cannot be fully explained by static, single-timepoint molecular profiling. Conventional bulk sequencing and first-generation single-cell RNA sequencing (scRNA-seq) guidelines rely critically on static endpoint analysis, creating data blind spots that completely eliminate the phylogenetic branching points and cell-microenvironment interaction dynamics that cells experience over time. Specifically, the cellular dissociation-induced structural disruption noise generated during tissue separation for transcriptomic analysis distorts complex cell-cell communication networks. Furthermore, these methods fail to computationally capture the dynamic equilibrium of defensive resistance feedback fluxes induced in response to exogenous perturbations, such as chemotherapy administration, repeatedly failing to secure optimal effective therapeutic and prophylactic drug concentrations at the clinical trial design stage. These static data bottlenecks have become a major obstacle in genomic R&D, ultimately leading to ambiguity in the mechanism of action in clinical trials and increasing the late-stage attrition rate in the pipeline.

Discovery: Single-Cell Tensor Synchronization and Downstream Evolutionary Topology Validation through the Operation of Multiple Recombinase and CRISPR Barcoding Modalities

This study implemented a sophisticatedly tuned recombinase cassette system, CRISPR molecular barcoding, and naturally occurring somatic mutations that function as in-cell genetic barcodes to achieve high-resolution cell lineage tracing. This modality synchronizes the entire process of individual cell division and differentiation onto a high-dimensional omics matrix tensor, enabling real-time clonal tracking. By proactively computing ligand-receptor occupancy free energy adjustment models and differentiation rate constants based on differential equations in silico, the platform predicts cell fate branching points from a systems biology perspective. This platform also incorporates a multi-batch effect computational removal algorithm to eliminate artificial bias in the analysis data. This represents a disruptive improvement over simple cell state mapping models, perfectly demonstrating the topological variation curves across the downstream transcriptomic network of cancer cells. Furthermore, by demonstrating the irreversible variation of clonal fitness at the genomic level, the study proves the complete molecular biological integrity of the lineage decoding technology.

Establishment of a Post-Genetic Epigenetic Lineage Adjustment and Reversible Cell Homeostasis Precision Layering Model

The multi-information obtained at single-cell resolution through cell lineage decoding is synchronized with a phylogenetic tensor in a tree-like manner, forming the foundation for a highly advanced precision stratification model. The researchers stratified the separation behavior of patient-specific genotypes and cell states based on multi-omics matrices collected from cancer microenvironments and aging tissues. Through this, they precisely captured the rate-limiting steps that determine disease progression and the biochemical reaction rate constants of regulatory factors. By artificially up-clamping or down-clamping the threshold activity of specific gene transcriptional networks within the target system in silico, they successfully completed a cell homeostasis autonomous tuning control backbone that allows cells to maintain dynamic reversibility within a normal range even under external harmful inductive stress.

Prospects: Establishing a Programmable Systems Biology Standard and Launching a Next-Generation IND Digital Governance System

Single-cell lineage tracing architecture heralds a full transition to a multi-dimensional tensor-based programmable precision medicine infrastructure that controls the patient's unique clonal dynamics, ending the era of static, single-point, post-hoc treatment frameworks. This next-generation computational platform is organically linked to the high-throughput screening stage of anticancer drug pipeline development in global large-scale biotech and multinational pharmaceutical companies (e.g., Roche, Novartis), providing a computational proprietary technology barrier that eliminates biological bias between different experimental batches. As a result, this computational system will not only meet the stringent technical specifications of companion diagnostics (CDx), a key element of digital healthcare, but will also serve as a unique digital governance master asset that instantly generates preclinical in-silico efficacy validation data at the Investigational New Drug (IND) application stage, which requires global regulatory approval, drastically shortening the timeline for obtaining regulatory approval.